Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265551 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00265551: Completed Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00265551 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00265551, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.
Interventions
- DRUG placebo
- DRUG SCA-136 (200 mg)
- DRUG SCA-136 (400 mg)
- DRUG olanzapine (15 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00265551 record still lists
NCT00265551 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00265551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00265551 about?
NCT00265551 is a clinical study titled "Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia". The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.
What is the current status of trial NCT00265551?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2006-01. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00265551?
The interventions under investigation include: placebo (DRUG), SCA-136 (200 mg) (DRUG), SCA-136 (400 mg) (DRUG), olanzapine (15 mg) (DRUG).
Who is sponsoring clinical trial NCT00265551?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00265551's enrollment target sits among peer trials
300 167th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia